KDR and neoplasm: Apatinib is a small-molecule antiangiogenic agent that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2) and also mildly inhibits c-Kit and c-Src tyrosine kinases.[7] Angiogenesis is an essential step in tumor growth and metastasis.